Mayo Clinic Laboratories is leading an evolution in autoimmune neurology diagnosis. Powered by expertise from our research labs, clinical labs, and Autoimmune Neurology Clinic, we have developed panels customized to address specific phenotypes. This approach delivers more clinically actionable results, providing a clear picture of the diagnosis, prognosis, and treatment options. These comprehensive neurological phenotype-specific evaluations should be considered first in patients suspected of autoimmune neurological disorders.
To better reflect this evolution in autoimmune neurology testing, and to reduce confusion and improve utilization for our clients, effective April 28, Mayo Clinic Laboratories is renaming our phenotype-specific evaluations to make it clear that they include both paraneoplastic antibodies and antibodies not associated with cancer.
For example (changes in bold):
In total, Mayo Clinic Laboratories will be updating the naming convention for fifteen of our phenotype-specific evaluations.
These disease-specific evaluations include encephalopathy, epilepsy, dementia, movement disorders, myelopathy, axonal neuropathy, dysautonomia, gastrointestinal dysmotility, and pediatric CNS. Each evaluation covers the spectrum of characterized antibodies (paraneoplastic and other autoimmune) reported for that phenotype (including multifocal disorders).